Publication | Closed Access

A phase 2, randomized, double-blind, placebo-controlled trial of clinical activity and safety of subcutaneous Å6 in women with asymptomatic CA125 progression after first-line chemotherapy of epithelial ovarian cancer

Epithelial Ovarian CancerMedicineGynecologyCancer TreatmentPhase 2OncologyRadiation OncologyGynecology OncologyClinical ActivityEndocrine-related CancerOvarian Cancer